Vol 3-1 Review Article

Amifostine is a Nephro-Protectant in Patients Receiving Treatment with Cisplatin- Myth, Mystery or Matter-of-Fact?

Sin Sil Ha1, Kazi Rubaina1,2, Chung-Shien Lee1,2, Veena John2, Nagashree Seetharamu2*

1St. John’s University, College of Pharmacy and Health Sciences, Department of Clinical Health Professions, 8000 Utopia Parkway, Queens, NY 11439, USA.

2Division of Medical Oncology and Hematology, Northwell Health Cancer Institute, Donald & Barbara Zucker School of Medicine at Hofstra/Northwell, 450 Lakeville Road, Lake Success, NY 11042, USA

Despite reports of amifostine possibly protecting nephrotoxicity from cisplatin, it has not been recommended by any guidelines committees or routinely prescribed in clinical practice over the past decade. In this article, we review literature and guidelines regarding use of amifostine in oncology practice for protection against adverse effects from certain chemotherapeutic agents, in particular as a nephro-protectant in patients receiving cisplatin.

View / Download Pdf
Vol 3-1 Commentary

Commentary: Cannabinoids in Urology. Which Benign Conditions Might they be Appropriate to Treat: A Systematic Review

Charles Taylor1*, Brian Birch1,2

1University of Southampton, Faculty of Medicine

2University Hospitals Southampton NHS FT, Southampton, UK

3Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

View / Download Pdf